MDNAF Projected Dividend Yield
Medicenna Therapeutics Corp ( OTCBB : MDNAF )Medicenna Therapeutics is a clinical-stage immunotherapy company developing engineered cytokines, Superkines, designed to improve the specificity, function and safety profile of interleukins. Co.'s Superkine Platform transforms Superkines into multi-functional therapies that modulate, dampen, amplify or fine-tune the immune system. Co.'s lead clinical program is MDNA11, a long-acting beta-enhanced not-alpha IL-2 super agonist. Co.'s most advanced candidate is bizaxofusp, a first-in-class IL-4 receptor (IL-4R) targeted therapy for the treatment of recurrent glioblastoma (rGBM), the most common and uniformly fatal form of brain cancer. 22 YEAR PERFORMANCE RESULTS |
|
MDNAF Dividend History Detail MDNAF Dividend News MDNAF Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |


